EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, F-59000 Lille, France.
Eur J Hosp Pharm. 2020 Mar;27(e1):e93-e98. doi: 10.1136/ejhpharm-2019-002146. Epub 2020 Feb 6.
Norepinephrine is a vasopressor frequently administered after dilution to treat hypotension and shocks in intensive care units. The stability of norepinephrine is known to be highly sensitive to storage conditions. Moreover, medication errors linked to the dilution step are frequent and may be deleterious for critically-ill patients, especially in intensive care units. This study aimed to evaluate the stability of ready-to-use diluted norepinephrine solutions prepared at two target concentrations (0.2 and 0.5 mg/mL), according to the summary of product characteristics, and stored for 365 days in two containers: AT-closed cyclic olefin copolymer vials, and polypropylene syringes.
A fast reversed-phase liquid chromatography method coupled with an ultra-violet detector was developed to assess the chemical stability of norepinephrine solutions. Validation was conducted according to the linearity of the calibration ranges, selectivity, sensitivity, accuracy and precision. Dosage, sub-visible particle contamination, pH monitoring and sterility assays were performed. Chemical stability was maintained if the measured concentration respected the lower limit of 90% of the initial concentration. Containers were stored at -20±5°C, +5±3°C and +25±2°C with 60±5% relative humidity in a dark closed enclosure.
Stability was successfully maintained for every concentration and container tested when stored at -20±5°C and +5±3°C. In these storage conditions, particle contamination, pH monitoring and sterility assay respected the required criteria. Chemical degradation and colouring of solutions appeared before the end of the 1 year study period for most norepinephrine solutions stored at room temperature.
Ready-to-use solutions containing 0.2 and 0.5 mg/mL norepinephrine in polypropylene syringes or cyclic olefin copolymer vials must be stored at refrigerated or frozen temperatures to obtain acceptable 1 year shelf-stability. Exposure to higher temperatures significantly decreases shelf-stability. Our study protocol for compounding polypropylene syringes and cyclic olefin copolymer vials containing norepinephrine is adapted to implementation in centralised intravenous additive services.
去甲肾上腺素是一种血管加压药,常经稀释后用于治疗重症监护病房的低血压和休克。已知去甲肾上腺素的稳定性对储存条件非常敏感。此外,与稀释步骤相关的用药错误频繁发生,可能对危重症患者造成损害,尤其是在重症监护病房。本研究旨在评估根据产品特性摘要制备的两种目标浓度(0.2 和 0.5mg/ml)的即用型稀释去甲肾上腺素溶液的稳定性,并将其储存在两种容器中 365 天:AT-封闭环烯烃共聚物小瓶和聚丙烯注射器。
开发了一种快速反相液相色谱法,结合紫外检测器,用于评估去甲肾上腺素溶液的化学稳定性。验证按照校准范围的线性、选择性、灵敏度、准确性和精密度进行。进行了剂量、亚可见颗粒污染、pH 值监测和无菌性检测。如果测量浓度符合初始浓度 90%下限,则认为化学稳定性得到维持。容器在 -20±5°C、+5±3°C 和 +25±2°C 下储存,相对湿度为 60±5%,在黑暗密闭环境中。
在 -20±5°C 和 +5±3°C 下储存时,每种浓度和容器的稳定性均成功维持。在这些储存条件下,颗粒污染、pH 值监测和无菌性检测符合要求标准。在室温下储存的大多数去甲肾上腺素溶液在 1 年研究期间结束前,溶液的化学降解和着色。
含有 0.2 和 0.5mg/ml 去甲肾上腺素的即用型聚丙烯注射器或环烯烃共聚物小瓶溶液必须冷藏或冷冻保存,以获得可接受的 1 年货架稳定性。暴露于较高温度会显著降低货架稳定性。我们用于配制含有去甲肾上腺素的聚丙烯注射器和环烯烃共聚物小瓶的化合物方案已适应于中央静脉添加剂服务的实施。